Cytokinetics
350 Oyster Point Blvd, South San Francisco, CA, 94080, United States
Overview
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 6
Sector focus
- Biopharma
- Biotechnology
- Health Care
Investment portfolio
- Imbria Pharmaceuticals
Participated · Series B · Apr 2025
Imbria Pharmaceuticals is a clinical-stage company focused on improving cardiac energetics to treat serious cardiovascular diseases. Its lead candidate, ninerafaxstat, is designed to enhance cardiac energy production without affecting heart rate, rhythm, ejection fraction, or blood pressure. The drug is currently being evaluated in FORTITUDE-HCM, a global Phase 2b trial for symptomatic non-obstructive hypertrophic cardiomyopathy, a condition with no approved treatments. The company’s strategy centers on positioning ninerafaxstat as a first-in-class therapy with broad cardiovascular applications. Recent Series B proceeds will fund continued clinical development and trial execution. The financing also expands Imbria’s board, adding representatives from new and existing investors, which may deepen strategic guidance and industry connections. Although the round size remains undisclosed, the expanded investor syndicate signals confidence in the company’s progress and future potential.